AIM Immunotech (NYSE American: AIM) has announced that the final patient has been dosed in the Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s (NYSE: AZN; LSE: AZN; STO: AZN) Imfinzi (durvalumab) in metastatic pancreatic cancer (MPC).
According to AIM, the study results are expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of MPC.
In a statement, Thomas K. Equels, CEO of AIM, commented, “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most likely to benefit from Ampligen-based therapy, thus supporting a more targeted and personalized treatment approach.”
